Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07558603 · ClinicalTrials.gov registry record · NA
Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist
A NA study, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- Not yet
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT07558603 is a NA study that has not yet begun recruiting, run by Goldman, Butterwick, Fitzpatrick and Groff. The registered enrollment target is 50 participants.
The verdict
NCT07558603, a NA study, has not yet begun recruiting, sponsored by Goldman, Butterwick, Fitzpatrick and Groff.
- NOT YET RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imaging, and reported adverse reactions.
Interventions
- DRUG On GLP1 plus HRT
- DRUG On GLP1 Only
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-04-20 |
| Est. Completion | 2026-11-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07558603
The ClinicalTrials.gov registry entry for NCT07558603 describes a study currently listed as not yet recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which On GLP1 plus HRT is the first listed.
NCT07558603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07558603 about?
NCT07558603 is a clinical study titled "Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist". The primary objective is to assess the safety and efficacy of the AGE Serum in improving the appearance of skin in post-menopausal subjects on HRT and non-HRT who are takingGLP-1 agonist therapy through the use of investigator assessments, subject questionnaires/assessments, photography, skin imagin...
What is the current status of trial NCT07558603?
This trial is currently not yet recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2026-04-20. Estimated completion is 2026-11-30.
What interventions are being tested in trial NCT07558603?
The interventions under investigation include: On GLP1 plus HRT (DRUG), On GLP1 Only (DRUG).
Who is sponsoring clinical trial NCT07558603?
This trial is sponsored by Goldman, Butterwick, Fitzpatrick and Groff, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.